May 12, 2026

Insider Reporting of Gifts: Impact on R&D?

According to a new study by B-school profs at The University of Cincinnati and Penn State, the accelerated reporting of gifts adopted as part of the SEC’s 2022 Rule 10b5-1 amendments and the SEC’s comments in related releases about the potential insider trading implications of well-timed gifts  may have had significant and unexpected consequences on corporate R&D expenditures.  Here’s an excerpt from the study’s abstract:

[W]e compare firms whose insiders historically concentrate stock gifts on unusually high-price days with other firms. We find that these treated firms significantly reduce R&D investment following the reform. The effect is strongest where opportunistic gift timing is likely most valuable and where insiders have greater discretion to influence investment policy.

In contrast, we fail to find a corresponding effect for firms whose insiders historically engage in opportunistic Rule 10b5-1 stock sales, helping isolate the gift-disclosure channel from other features of the amendment. Overall, our evidence suggests that a disclosure reform aimed at curbing opportunistic insider behavior had the unintended consequence of reducing corporate risk-taking.

One of the study’s authors summarized its implications in a LinkedIn post:

The key takeaway is that a disclosure reform designed to curb insider opportunism may have had real effects on corporate investment. More broadly, personal tax-planning opportunities can shape insiders’ willingness to support risky corporate policies, and regulatory changes that constrain those opportunities can affect firm decisions in ways that extend well beyond the regulated transaction itself.

John Jenkins

Take Me Back to the Main Blog Page

Blog Preferences: Subscribe, unsubscribe, or change the frequency of email notifications for this blog.

UPDATE EMAIL PREFERENCES

Try Out The Full Member Experience: Not a member of TheCorporateCounsel.net? Start a free trial to explore the benefits of membership.

START MY FREE TRIAL